Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main Page
My Profile
My Assessments
My Life Story
Med Classes
Problems
Recent changes
Pharmacopedia
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Drilldown: Medicines
English
Tools
Tools
move to sidebar
hide
Actions
General
Printable version
Appearance
move to sidebar
hide
Choose a table:
Medicines (732)
Medicines
> uses:
'"`UNIQ--vote-00000669-QINU`"'
&
fda max:
20 mg/d
Use the filters below to narrow your results.
generic:
Vardenafil (1)
brand:
Levitra, Staxyn (1)
classes:
PDE5 Inhibitor (1)
mechanism:
Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1)
uses:
(Click arrow to add another value)
None
·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"'
·
'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"'
·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"'
·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"'
·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"'
·
'"`UNIQ--vote-00000006-QINU`"'
·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"'
·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"'
·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"'
·
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"'
·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"'
·
Preventive treatment of migraine in adults (episodic and chronic)
·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"'
·
(investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"'
·
Acute treatment of migraine with or without aura in adults
·
ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult)
·
ADHD, narcolepsy
·
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD.
·
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024
Other values:
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023
Antimanic, Antidepressive, Antisuicide
Chronic migraine (≥15 headache days/month), cervical dystonia, blepharospasm, hyperhidrosis, overactive bladder, urinary incontinence, strabismus, spasticity, cosmetic problems
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA)
Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019)
Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression.
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease.
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019)
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022)
Investigational for major depressive disorder; trials underway (phase 3 mixed results)
Major depressive disorder in adults (FDA-approved 2011)
Major depressive disorder in adults (FDA-approved 2013). Notable for evidence of cognitive benefit (processing speed) that distinguishes it from other antidepressants.
Major depressive disorder in adults (FDA-approved August 2022)
Mild to moderate pain; cough suppression (low-dose).
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
Pain, cough, disquiet
Postpartum depression (PPD) in adults
Postpartum depression (PPD) in adults (FDA-approved 2023)
Preventive treatment of migraine in adults
Preventive treatment of migraine in adults; episodic cluster headache
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022).
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline).
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021).
Schizophrenia, acute psychosis, agitation, delirium, Tourette syndrome, severe nausea
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020).
[[Type 2 diabetes mellitus]] (adjunct, second-line)
[[Type 2 diabetes mellitus]] (incl. pediatric ≥10 y) · [[Obesity]] (incl. pediatric ≥12 y) · [[Cardiovascular risk reduction]] in T2DM
[[Type 2 diabetes mellitus]] · [[Cardiovascular risk reduction]] in T2DM
[[Type 2 diabetes mellitus]] · [[Obesity]] · [[Cardiovascular risk reduction]] in obesity without diabetes · [[MASH]] with stage 2–3 fibrosis · [[Chronic kidney disease]] in T2DM
[[Type 2 diabetes mellitus]] · [[Obesity]] · [[Obstructive sleep apnea]] in obesity
'"`UNIQ--vote-0000000C-QINU`"', '"`UNIQ--vote-0000000D-QINU`"', '"`UNIQ--vote-0000000E-QINU`"', '"`UNIQ--vote-0000000F-QINU`"'
'"`UNIQ--vote-00000011-QINU`"'
'"`UNIQ--vote-00000013-QINU`"'
'"`UNIQ--vote-00000017-QINU`"'
'"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"'
'"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"'
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"'
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"'
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"'
'"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"'
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"'
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"'
'"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"'
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"'
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"'
'"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"', '"`UNIQ--vote-00000029-QINU`"', '"`UNIQ--vote-0000002A-QINU`"'
'"`UNIQ--vote-00000033-QINU`"', '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"'
'"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"'
'"`UNIQ--vote-00000039-QINU`"', '"`UNIQ--vote-0000003A-QINU`"', '"`UNIQ--vote-0000003B-QINU`"', '"`UNIQ--vote-0000003C-QINU`"', '"`UNIQ--vote-0000003D-QINU`"'
'"`UNIQ--vote-00000040-QINU`"'
'"`UNIQ--vote-00000042-QINU`"', '"`UNIQ--vote-00000043-QINU`"', '"`UNIQ--vote-00000044-QINU`"'
'"`UNIQ--vote-00000050-QINU`"'
'"`UNIQ--vote-00000055-QINU`"', '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"', '"`UNIQ--vote-00000058-QINU`"'
'"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"'
'"`UNIQ--vote-00000063-QINU`"', '"`UNIQ--vote-00000064-QINU`"'
'"`UNIQ--vote-00000065-QINU`"'
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"'
'"`UNIQ--vote-00000075-QINU`"', '"`UNIQ--vote-00000076-QINU`"', '"`UNIQ--vote-00000077-QINU`"'
'"`UNIQ--vote-00000088-QINU`"', '"`UNIQ--vote-00000089-QINU`"', '"`UNIQ--vote-0000008A-QINU`"', '"`UNIQ--vote-0000008B-QINU`"'
'"`UNIQ--vote-0000008F-QINU`"', '"`UNIQ--vote-00000090-QINU`"', '"`UNIQ--vote-00000091-QINU`"', '"`UNIQ--vote-00000092-QINU`"'
'"`UNIQ--vote-00000095-QINU`"', '"`UNIQ--vote-00000096-QINU`"'
'"`UNIQ--vote-00000095-QINU`"', '"`UNIQ--vote-00000096-QINU`"', '"`UNIQ--vote-00000097-QINU`"', '"`UNIQ--vote-00000098-QINU`"'
'"`UNIQ--vote-000000AD-QINU`"', '"`UNIQ--vote-000000AE-QINU`"'
'"`UNIQ--vote-000000B8-QINU`"', '"`UNIQ--vote-000000B9-QINU`"', '"`UNIQ--vote-000000BA-QINU`"', '"`UNIQ--vote-000000BB-QINU`"'
'"`UNIQ--vote-000000CF-QINU`"', '"`UNIQ--vote-000000D0-QINU`"', '"`UNIQ--vote-000000D1-QINU`"'
'"`UNIQ--vote-000000DA-QINU`"', '"`UNIQ--vote-000000DB-QINU`"', '"`UNIQ--vote-000000DC-QINU`"', '"`UNIQ--vote-000000DD-QINU`"'
'"`UNIQ--vote-000000F9-QINU`"', '"`UNIQ--vote-000000FA-QINU`"', '"`UNIQ--vote-000000FB-QINU`"'
'"`UNIQ--vote-00000119-QINU`"', '"`UNIQ--vote-0000011A-QINU`"', '"`UNIQ--vote-0000011B-QINU`"', '"`UNIQ--vote-0000011C-QINU`"'
'"`UNIQ--vote-0000013A-QINU`"', '"`UNIQ--vote-0000013B-QINU`"', '"`UNIQ--vote-0000013C-QINU`"', '"`UNIQ--vote-0000013D-QINU`"'
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"'
'"`UNIQ--vote-0000015B-QINU`"', '"`UNIQ--vote-0000015C-QINU`"', '"`UNIQ--vote-0000015D-QINU`"'
'"`UNIQ--vote-00000178-QINU`"', '"`UNIQ--vote-00000179-QINU`"'
'"`UNIQ--vote-0000019B-QINU`"', '"`UNIQ--vote-0000019C-QINU`"', '"`UNIQ--vote-0000019D-QINU`"', '"`UNIQ--vote-0000019E-QINU`"', '"`UNIQ--vote-0000019F-QINU`"', '"`UNIQ--vote-000001A0-QINU`"'
'"`UNIQ--vote-000001BA-QINU`"', '"`UNIQ--vote-000001BB-QINU`"'
'"`UNIQ--vote-000001D9-QINU`"', '"`UNIQ--vote-000001DA-QINU`"', '"`UNIQ--vote-000001DB-QINU`"', '"`UNIQ--vote-000001DC-QINU`"'
'"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"'
'"`UNIQ--vote-0000021C-QINU`"', '"`UNIQ--vote-0000021D-QINU`"', '"`UNIQ--vote-0000021E-QINU`"', '"`UNIQ--vote-0000021F-QINU`"', '"`UNIQ--vote-00000220-QINU`"', '"`UNIQ--vote-00000221-QINU`"'
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"'
'"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"'
'"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"'
'"`UNIQ--vote-0000029D-QINU`"', '"`UNIQ--vote-0000029E-QINU`"', '"`UNIQ--vote-0000029F-QINU`"', '"`UNIQ--vote-000002A0-QINU`"', '"`UNIQ--vote-000002A1-QINU`"', '"`UNIQ--vote-000002A2-QINU`"'
'"`UNIQ--vote-000002C0-QINU`"', '"`UNIQ--vote-000002C1-QINU`"', '"`UNIQ--vote-000002C2-QINU`"', '"`UNIQ--vote-000002C3-QINU`"'
'"`UNIQ--vote-000002C1-QINU`"'
'"`UNIQ--vote-000002D8-QINU`"'
'"`UNIQ--vote-000002EE-QINU`"', '"`UNIQ--vote-000002EF-QINU`"'
'"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"'
'"`UNIQ--vote-0000032C-QINU`"', '"`UNIQ--vote-0000032D-QINU`"', '"`UNIQ--vote-0000032E-QINU`"', '"`UNIQ--vote-0000032F-QINU`"'
'"`UNIQ--vote-0000034F-QINU`"', '"`UNIQ--vote-00000350-QINU`"', '"`UNIQ--vote-00000351-QINU`"', '"`UNIQ--vote-00000352-QINU`"', '"`UNIQ--vote-00000353-QINU`"'
'"`UNIQ--vote-00000374-QINU`"', '"`UNIQ--vote-00000375-QINU`"', '"`UNIQ--vote-00000376-QINU`"', '"`UNIQ--vote-00000377-QINU`"'
'"`UNIQ--vote-00000393-QINU`"', '"`UNIQ--vote-00000394-QINU`"', '"`UNIQ--vote-00000395-QINU`"'
'"`UNIQ--vote-000003A0-QINU`"', '"`UNIQ--vote-000003A1-QINU`"'
'"`UNIQ--vote-000003B5-QINU`"', '"`UNIQ--vote-000003B6-QINU`"', '"`UNIQ--vote-000003B7-QINU`"', '"`UNIQ--vote-000003B8-QINU`"', '"`UNIQ--vote-000003B9-QINU`"'
'"`UNIQ--vote-000003D3-QINU`"', '"`UNIQ--vote-000003D4-QINU`"'
'"`UNIQ--vote-000003F6-QINU`"', '"`UNIQ--vote-000003F7-QINU`"', '"`UNIQ--vote-000003F8-QINU`"', '"`UNIQ--vote-000003F9-QINU`"', '"`UNIQ--vote-000003FA-QINU`"', '"`UNIQ--vote-000003FB-QINU`"'
'"`UNIQ--vote-00000415-QINU`"', '"`UNIQ--vote-00000416-QINU`"'
'"`UNIQ--vote-0000042D-QINU`"', '"`UNIQ--vote-0000042E-QINU`"', '"`UNIQ--vote-0000042F-QINU`"', '"`UNIQ--vote-00000430-QINU`"'
'"`UNIQ--vote-0000044C-QINU`"', '"`UNIQ--vote-0000044D-QINU`"', '"`UNIQ--vote-0000044E-QINU`"', '"`UNIQ--vote-0000044F-QINU`"'
'"`UNIQ--vote-00000468-QINU`"'
'"`UNIQ--vote-00000475-QINU`"', '"`UNIQ--vote-00000476-QINU`"', '"`UNIQ--vote-00000477-QINU`"', '"`UNIQ--vote-00000478-QINU`"', '"`UNIQ--vote-00000479-QINU`"', '"`UNIQ--vote-0000047A-QINU`"', '"`UNIQ--vote-0000047B-QINU`"', '"`UNIQ--vote-0000047C-QINU`"'
'"`UNIQ--vote-00000491-QINU`"'
'"`UNIQ--vote-000004AB-QINU`"', '"`UNIQ--vote-000004AC-QINU`"'
'"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"'
'"`UNIQ--vote-000004CA-QINU`"', '"`UNIQ--vote-000004CB-QINU`"', '"`UNIQ--vote-000004CC-QINU`"'
'"`UNIQ--vote-000004ED-QINU`"', '"`UNIQ--vote-000004EE-QINU`"', '"`UNIQ--vote-000004EF-QINU`"', '"`UNIQ--vote-000004F0-QINU`"', '"`UNIQ--vote-000004F1-QINU`"'
'"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"'
'"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"'
'"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"'
'"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"'
'"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"'
'"`UNIQ--vote-0000056B-QINU`"'
'"`UNIQ--vote-00000586-QINU`"', '"`UNIQ--vote-00000587-QINU`"', '"`UNIQ--vote-00000588-QINU`"'
'"`UNIQ--vote-0000059A-QINU`"', '"`UNIQ--vote-0000059B-QINU`"'
'"`UNIQ--vote-0000059D-QINU`"'
'"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"'
'"`UNIQ--vote-000005D0-QINU`"', '"`UNIQ--vote-000005D1-QINU`"', '"`UNIQ--vote-000005D2-QINU`"'
'"`UNIQ--vote-000005D2-QINU`"', '"`UNIQ--vote-000005D3-QINU`"', '"`UNIQ--vote-000005D4-QINU`"', '"`UNIQ--vote-000005D5-QINU`"'
'"`UNIQ--vote-000005E7-QINU`"', '"`UNIQ--vote-000005E8-QINU`"', '"`UNIQ--vote-000005E9-QINU`"', '"`UNIQ--vote-000005EA-QINU`"', '"`UNIQ--vote-000005EB-QINU`"'
'"`UNIQ--vote-000005EF-QINU`"', '"`UNIQ--vote-000005F0-QINU`"', '"`UNIQ--vote-000005F1-QINU`"'
'"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"'
'"`UNIQ--vote-0000061F-QINU`"', '"`UNIQ--vote-00000620-QINU`"'
'"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"'
'"`UNIQ--vote-0000063E-QINU`"', '"`UNIQ--vote-0000063F-QINU`"', '"`UNIQ--vote-00000640-QINU`"', '"`UNIQ--vote-00000641-QINU`"'
'"`UNIQ--vote-00000661-QINU`"', '"`UNIQ--vote-00000662-QINU`"', '"`UNIQ--vote-00000663-QINU`"', '"`UNIQ--vote-00000664-QINU`"', '"`UNIQ--vote-00000665-QINU`"'
'"`UNIQ--vote-00000669-QINU`"'
'"`UNIQ--vote-00000683-QINU`"', '"`UNIQ--vote-00000684-QINU`"', '"`UNIQ--vote-00000685-QINU`"', '"`UNIQ--vote-00000686-QINU`"'
'"`UNIQ--vote-0000069B-QINU`"', '"`UNIQ--vote-0000069C-QINU`"'
'"`UNIQ--vote-000006A2-QINU`"', '"`UNIQ--vote-000006A3-QINU`"', '"`UNIQ--vote-000006A4-QINU`"'
'"`UNIQ--vote-000006C0-QINU`"', '"`UNIQ--vote-000006C1-QINU`"', '"`UNIQ--vote-000006C2-QINU`"'
'"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"'
'"`UNIQ--vote-00000700-QINU`"', '"`UNIQ--vote-00000701-QINU`"', '"`UNIQ--vote-00000702-QINU`"', '"`UNIQ--vote-00000703-QINU`"', '"`UNIQ--vote-00000704-QINU`"'
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"'
'"`UNIQ--vote-00000717-QINU`"', '"`UNIQ--vote-00000718-QINU`"', '"`UNIQ--vote-00000719-QINU`"'
'"`UNIQ--vote-00000722-QINU`"', '"`UNIQ--vote-00000723-QINU`"', '"`UNIQ--vote-00000724-QINU`"', '"`UNIQ--vote-00000725-QINU`"'
'"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"'
'"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"'
'"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"', '"`UNIQ--vote-00000749-QINU`"', '"`UNIQ--vote-0000074A-QINU`"', '"`UNIQ--vote-0000074B-QINU`"', '"`UNIQ--vote-0000074C-QINU`"'
'"`UNIQ--vote-00000758-QINU`"', '"`UNIQ--vote-00000759-QINU`"', '"`UNIQ--vote-0000075A-QINU`"'
'"`UNIQ--vote-00000764-QINU`"'
'"`UNIQ--vote-00000780-QINU`"', '"`UNIQ--vote-00000781-QINU`"', '"`UNIQ--vote-00000782-QINU`"'
'"`UNIQ--vote-0000079C-QINU`"', '"`UNIQ--vote-0000079D-QINU`"'
'"`UNIQ--vote-000007C1-QINU`"', '"`UNIQ--vote-000007C2-QINU`"', '"`UNIQ--vote-000007C3-QINU`"', '"`UNIQ--vote-000007C4-QINU`"', '"`UNIQ--vote-000007C5-QINU`"', '"`UNIQ--vote-000007C6-QINU`"', '"`UNIQ--vote-000007C7-QINU`"'
'"`UNIQ--vote-000007E7-QINU`"', '"`UNIQ--vote-000007E8-QINU`"', '"`UNIQ--vote-000007E9-QINU`"', '"`UNIQ--vote-000007EA-QINU`"', '"`UNIQ--vote-000007EB-QINU`"'
'"`UNIQ--vote-00000805-QINU`"', '"`UNIQ--vote-00000806-QINU`"'
'"`UNIQ--vote-0000081E-QINU`"'
'"`UNIQ--vote-00000822-QINU`"', '"`UNIQ--vote-00000823-QINU`"'
'"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"'
'"`UNIQ--vote-00000862-QINU`"', '"`UNIQ--vote-00000863-QINU`"', '"`UNIQ--vote-00000864-QINU`"', '"`UNIQ--vote-00000865-QINU`"', '"`UNIQ--vote-00000866-QINU`"'
'"`UNIQ--vote-00000884-QINU`"', '"`UNIQ--vote-00000885-QINU`"', '"`UNIQ--vote-00000886-QINU`"', '"`UNIQ--vote-00000887-QINU`"'
'"`UNIQ--vote-000008A1-QINU`"', '"`UNIQ--vote-000008A2-QINU`"'
'"`UNIQ--vote-000008C0-QINU`"', '"`UNIQ--vote-000008C1-QINU`"', '"`UNIQ--vote-000008C2-QINU`"', '"`UNIQ--vote-000008C3-QINU`"'
'"`UNIQ--vote-000008E3-QINU`"', '"`UNIQ--vote-000008E4-QINU`"', '"`UNIQ--vote-000008E5-QINU`"', '"`UNIQ--vote-000008E6-QINU`"', '"`UNIQ--vote-000008E7-QINU`"'
'"`UNIQ--vote-00000909-QINU`"', '"`UNIQ--vote-0000090A-QINU`"', '"`UNIQ--vote-0000090B-QINU`"', '"`UNIQ--vote-0000090C-QINU`"', '"`UNIQ--vote-0000090D-QINU`"', '"`UNIQ--vote-0000090E-QINU`"'
'"`UNIQ--vote-00000932-QINU`"', '"`UNIQ--vote-00000933-QINU`"', '"`UNIQ--vote-00000934-QINU`"', '"`UNIQ--vote-00000935-QINU`"', '"`UNIQ--vote-00000936-QINU`"', '"`UNIQ--vote-00000937-QINU`"'
'"`UNIQ--vote-00000952-QINU`"', '"`UNIQ--vote-00000953-QINU`"'
'"`UNIQ--vote-00000977-QINU`"', '"`UNIQ--vote-00000978-QINU`"', '"`UNIQ--vote-00000979-QINU`"', '"`UNIQ--vote-0000097A-QINU`"', '"`UNIQ--vote-0000097B-QINU`"'
'"`UNIQ--vote-0000099F-QINU`"', '"`UNIQ--vote-000009A0-QINU`"', '"`UNIQ--vote-000009A1-QINU`"', '"`UNIQ--vote-000009A2-QINU`"', '"`UNIQ--vote-000009A3-QINU`"', '"`UNIQ--vote-000009A4-QINU`"'
'"`UNIQ--vote-000009BE-QINU`"', '"`UNIQ--vote-000009BF-QINU`"'
'"`UNIQ--vote-000009DF-QINU`"', '"`UNIQ--vote-000009E0-QINU`"', '"`UNIQ--vote-000009E1-QINU`"', '"`UNIQ--vote-000009E2-QINU`"', '"`UNIQ--vote-000009E3-QINU`"'
'"`UNIQ--vote-000009FF-QINU`"', '"`UNIQ--vote-00000A00-QINU`"', '"`UNIQ--vote-00000A01-QINU`"'
'"`UNIQ--vote-00000A1F-QINU`"', '"`UNIQ--vote-00000A20-QINU`"', '"`UNIQ--vote-00000A21-QINU`"'
'"`UNIQ--vote-00000A42-QINU`"', '"`UNIQ--vote-00000A43-QINU`"', '"`UNIQ--vote-00000A44-QINU`"', '"`UNIQ--vote-00000A45-QINU`"', '"`UNIQ--vote-00000A46-QINU`"'
'"`UNIQ--vote-00000A66-QINU`"', '"`UNIQ--vote-00000A67-QINU`"', '"`UNIQ--vote-00000A68-QINU`"', '"`UNIQ--vote-00000A69-QINU`"', '"`UNIQ--vote-00000A6A-QINU`"'
'"`UNIQ--vote-00000A8C-QINU`"', '"`UNIQ--vote-00000A8D-QINU`"', '"`UNIQ--vote-00000A8E-QINU`"', '"`UNIQ--vote-00000A8F-QINU`"', '"`UNIQ--vote-00000A90-QINU`"'
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"'
'"`UNIQ--vote-00000ACD-QINU`"', '"`UNIQ--vote-00000ACE-QINU`"', '"`UNIQ--vote-00000ACF-QINU`"', '"`UNIQ--vote-00000AD0-QINU`"'
'"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"'
'"`UNIQ--vote-00000B08-QINU`"', '"`UNIQ--vote-00000B09-QINU`"'
'"`UNIQ--vote-00000B23-QINU`"', '"`UNIQ--vote-00000B24-QINU`"'
'"`UNIQ--vote-00000B42-QINU`"', '"`UNIQ--vote-00000B43-QINU`"', '"`UNIQ--vote-00000B44-QINU`"', '"`UNIQ--vote-00000B45-QINU`"'
'"`UNIQ--vote-00000B61-QINU`"', '"`UNIQ--vote-00000B62-QINU`"', '"`UNIQ--vote-00000B63-QINU`"'
'"`UNIQ--vote-00000B81-QINU`"', '"`UNIQ--vote-00000B82-QINU`"', '"`UNIQ--vote-00000B83-QINU`"'
'"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"'
'"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"'
'"`UNIQ--vote-00000BE3-QINU`"', '"`UNIQ--vote-00000BE4-QINU`"', '"`UNIQ--vote-00000BE5-QINU`"', '"`UNIQ--vote-00000BE6-QINU`"', '"`UNIQ--vote-00000BE7-QINU`"', '"`UNIQ--vote-00000BE8-QINU`"', '"`UNIQ--vote-00000BE9-QINU`"', '"`UNIQ--vote-00000BEA-QINU`"'
'"`UNIQ--vote-00000C0A-QINU`"', '"`UNIQ--vote-00000C0B-QINU`"', '"`UNIQ--vote-00000C0C-QINU`"', '"`UNIQ--vote-00000C0D-QINU`"', '"`UNIQ--vote-00000C0E-QINU`"'
'"`UNIQ--vote-00000C2E-QINU`"', '"`UNIQ--vote-00000C2F-QINU`"', '"`UNIQ--vote-00000C30-QINU`"', '"`UNIQ--vote-00000C31-QINU`"'
'"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"'
'"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"'
'"`UNIQ--vote-00000C8F-QINU`"', '"`UNIQ--vote-00000C90-QINU`"', '"`UNIQ--vote-00000C91-QINU`"'
'"`UNIQ--vote-00000CB0-QINU`"', '"`UNIQ--vote-00000CB1-QINU`"', '"`UNIQ--vote-00000CB2-QINU`"'
'"`UNIQ--vote-00000CCA-QINU`"', '"`UNIQ--vote-00000CCB-QINU`"'
'"`UNIQ--vote-00000CEF-QINU`"', '"`UNIQ--vote-00000CF0-QINU`"', '"`UNIQ--vote-00000CF1-QINU`"', '"`UNIQ--vote-00000CF2-QINU`"', '"`UNIQ--vote-00000CF3-QINU`"', '"`UNIQ--vote-00000CF4-QINU`"'
'"`UNIQ--vote-00000D13-QINU`"', '"`UNIQ--vote-00000D14-QINU`"', '"`UNIQ--vote-00000D15-QINU`"', '"`UNIQ--vote-00000D16-QINU`"'
'"`UNIQ--vote-00000D38-QINU`"', '"`UNIQ--vote-00000D39-QINU`"', '"`UNIQ--vote-00000D3A-QINU`"', '"`UNIQ--vote-00000D3B-QINU`"', '"`UNIQ--vote-00000D3C-QINU`"', '"`UNIQ--vote-00000D3D-QINU`"'
'"`UNIQ--vote-00000D57-QINU`"', '"`UNIQ--vote-00000D58-QINU`"'
'"`UNIQ--vote-00000D7C-QINU`"', '"`UNIQ--vote-00000D7D-QINU`"', '"`UNIQ--vote-00000D7E-QINU`"', '"`UNIQ--vote-00000D7F-QINU`"', '"`UNIQ--vote-00000D80-QINU`"', '"`UNIQ--vote-00000D81-QINU`"'
'"`UNIQ--vote-00000D9E-QINU`"', '"`UNIQ--vote-00000D9F-QINU`"', '"`UNIQ--vote-00000DA0-QINU`"'
'"`UNIQ--vote-00000DBE-QINU`"', '"`UNIQ--vote-00000DBF-QINU`"', '"`UNIQ--vote-00000DC0-QINU`"', '"`UNIQ--vote-00000DC1-QINU`"'
'"`UNIQ--vote-00000DDF-QINU`"', '"`UNIQ--vote-00000DE0-QINU`"', '"`UNIQ--vote-00000DE1-QINU`"', '"`UNIQ--vote-00000DE2-QINU`"'
'"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"'
'"`UNIQ--vote-00000E23-QINU`"', '"`UNIQ--vote-00000E24-QINU`"', '"`UNIQ--vote-00000E25-QINU`"', '"`UNIQ--vote-00000E26-QINU`"', '"`UNIQ--vote-00000E27-QINU`"', '"`UNIQ--vote-00000E28-QINU`"', '"`UNIQ--vote-00000E29-QINU`"', '"`UNIQ--vote-00000E2A-QINU`"'
'"`UNIQ--vote-00000E4C-QINU`"', '"`UNIQ--vote-00000E4D-QINU`"', '"`UNIQ--vote-00000E4E-QINU`"', '"`UNIQ--vote-00000E4F-QINU`"', '"`UNIQ--vote-00000E50-QINU`"', '"`UNIQ--vote-00000E51-QINU`"'
'"`UNIQ--vote-00000E71-QINU`"', '"`UNIQ--vote-00000E72-QINU`"', '"`UNIQ--vote-00000E73-QINU`"', '"`UNIQ--vote-00000E74-QINU`"', '"`UNIQ--vote-00000E75-QINU`"'
'"`UNIQ--vote-00000E91-QINU`"', '"`UNIQ--vote-00000E92-QINU`"', '"`UNIQ--vote-00000E93-QINU`"'
'"`UNIQ--vote-00000EAF-QINU`"', '"`UNIQ--vote-00000EB0-QINU`"', '"`UNIQ--vote-00000EB1-QINU`"'
'"`UNIQ--vote-00000ECF-QINU`"', '"`UNIQ--vote-00000ED0-QINU`"', '"`UNIQ--vote-00000ED1-QINU`"', '"`UNIQ--vote-00000ED2-QINU`"'
'"`UNIQ--vote-00000EF4-QINU`"', '"`UNIQ--vote-00000EF5-QINU`"', '"`UNIQ--vote-00000EF6-QINU`"', '"`UNIQ--vote-00000EF7-QINU`"', '"`UNIQ--vote-00000EF8-QINU`"'
'"`UNIQ--vote-00000F1B-QINU`"', '"`UNIQ--vote-00000F1C-QINU`"', '"`UNIQ--vote-00000F1D-QINU`"', '"`UNIQ--vote-00000F1E-QINU`"', '"`UNIQ--vote-00000F1F-QINU`"'
'"`UNIQ--vote-00000F40-QINU`"', '"`UNIQ--vote-00000F41-QINU`"', '"`UNIQ--vote-00000F42-QINU`"', '"`UNIQ--vote-00000F43-QINU`"', '"`UNIQ--vote-00000F44-QINU`"'
'"`UNIQ--vote-00000F5C-QINU`"', '"`UNIQ--vote-00000F5D-QINU`"'
'"`UNIQ--vote-00000F78-QINU`"', '"`UNIQ--vote-00000F79-QINU`"', '"`UNIQ--vote-00000F7A-QINU`"'
'"`UNIQ--vote-00000F98-QINU`"', '"`UNIQ--vote-00000F99-QINU`"', '"`UNIQ--vote-00000F9A-QINU`"', '"`UNIQ--vote-00000F9B-QINU`"'
'"`UNIQ--vote-00000FB3-QINU`"', '''adjunctive only''' (does not treat the underlying infection)
'"`UNIQ--vote-00000FCF-QINU`"', '"`UNIQ--vote-00000FD0-QINU`"', '"`UNIQ--vote-00000FD1-QINU`"'
'"`UNIQ--vote-00000FF3-QINU`"', '"`UNIQ--vote-00000FF4-QINU`"', '"`UNIQ--vote-00000FF5-QINU`"', '"`UNIQ--vote-00000FF6-QINU`"', '"`UNIQ--vote-00000FF7-QINU`"', '"`UNIQ--vote-00000FF8-QINU`"'
'"`UNIQ--vote-00001016-QINU`"', '"`UNIQ--vote-00001017-QINU`"', '"`UNIQ--vote-00001018-QINU`"', '"`UNIQ--vote-00001019-QINU`"'
'"`UNIQ--vote-00001035-QINU`"', '"`UNIQ--vote-00001036-QINU`"', '"`UNIQ--vote-00001037-QINU`"'
'"`UNIQ--vote-0000104E-QINU`"', '"`UNIQ--vote-0000104F-QINU`"'
'"`UNIQ--vote-00001069-QINU`"', '"`UNIQ--vote-0000106A-QINU`"'
'"`UNIQ--vote-0000108C-QINU`"', '"`UNIQ--vote-0000108D-QINU`"', '"`UNIQ--vote-0000108E-QINU`"', '"`UNIQ--vote-0000108F-QINU`"', '"`UNIQ--vote-00001090-QINU`"', '"`UNIQ--vote-00001091-QINU`"'
'"`UNIQ--vote-000010AF-QINU`"', '"`UNIQ--vote-000010B0-QINU`"', '"`UNIQ--vote-000010B1-QINU`"', '"`UNIQ--vote-000010B2-QINU`"'
'"`UNIQ--vote-000010CE-QINU`"', '"`UNIQ--vote-000010CF-QINU`"', '"`UNIQ--vote-000010D0-QINU`"'
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"'
'"`UNIQ--vote-0000113C-QINU`"', '"`UNIQ--vote-0000113D-QINU`"', '"`UNIQ--vote-0000113E-QINU`"'
'"`UNIQ--vote-0000115F-QINU`"', '"`UNIQ--vote-00001160-QINU`"', '"`UNIQ--vote-00001161-QINU`"', '"`UNIQ--vote-00001162-QINU`"', '"`UNIQ--vote-00001163-QINU`"'
'"`UNIQ--vote-0000117B-QINU`"'
'"`UNIQ--vote-00001199-QINU`"', '"`UNIQ--vote-0000119A-QINU`"', '"`UNIQ--vote-0000119B-QINU`"'
'"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"'
'"`UNIQ--vote-000011D7-QINU`"', '"`UNIQ--vote-000011D8-QINU`"'
'"`UNIQ--vote-000011F6-QINU`"', '"`UNIQ--vote-000011F7-QINU`"', '"`UNIQ--vote-000011F8-QINU`"'
'"`UNIQ--vote-00001215-QINU`"', '"`UNIQ--vote-00001216-QINU`"', '"`UNIQ--vote-00001217-QINU`"'
'"`UNIQ--vote-00001235-QINU`"', '"`UNIQ--vote-00001236-QINU`"', '"`UNIQ--vote-00001237-QINU`"', '"`UNIQ--vote-00001238-QINU`"'
'"`UNIQ--vote-0000124D-QINU`"', '"`UNIQ--vote-0000124E-QINU`"', '"`UNIQ--vote-0000124F-QINU`"'
'"`UNIQ--vote-0000126B-QINU`"', '"`UNIQ--vote-0000126C-QINU`"', '"`UNIQ--vote-0000126D-QINU`"'
'"`UNIQ--vote-00001286-QINU`"'
'"`UNIQ--vote-0000129E-QINU`"'
'"`UNIQ--vote-000012B7-QINU`"', '"`UNIQ--vote-000012B8-QINU`"', '"`UNIQ--vote-000012B9-QINU`"', '"`UNIQ--vote-000012BA-QINU`"', '"`UNIQ--vote-000012BB-QINU`"'
'"`UNIQ--vote-000012CE-QINU`"', '"`UNIQ--vote-000012CF-QINU`"', '"`UNIQ--vote-000012D0-QINU`"'
'"`UNIQ--vote-000012E5-QINU`"', '"`UNIQ--vote-000012E6-QINU`"', '"`UNIQ--vote-000012E7-QINU`"', '"`UNIQ--vote-000012E8-QINU`"'
'"`UNIQ--vote-00001303-QINU`"', '"`UNIQ--vote-00001304-QINU`"', '"`UNIQ--vote-00001305-QINU`"', '"`UNIQ--vote-00001306-QINU`"', '"`UNIQ--vote-00001307-QINU`"', '"`UNIQ--vote-00001308-QINU`"', '"`UNIQ--vote-00001309-QINU`"'
'"`UNIQ--vote-0000131A-QINU`"', '"`UNIQ--vote-0000131B-QINU`"'
'"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"'
'"`UNIQ--vote-00001341-QINU`"', '"`UNIQ--vote-00001342-QINU`"'
'"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"'
'"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"'
'"`UNIQ--vote-00001393-QINU`"', '"`UNIQ--vote-00001394-QINU`"', '"`UNIQ--vote-00001395-QINU`"', '"`UNIQ--vote-00001396-QINU`"', '"`UNIQ--vote-00001397-QINU`"'
'"`UNIQ--vote-000013B3-QINU`"', '"`UNIQ--vote-000013B4-QINU`"', '"`UNIQ--vote-000013B5-QINU`"'
'"`UNIQ--vote-000013CF-QINU`"', '"`UNIQ--vote-000013D0-QINU`"'
'"`UNIQ--vote-000013F0-QINU`"', '"`UNIQ--vote-000013F1-QINU`"', '"`UNIQ--vote-000013F2-QINU`"', '"`UNIQ--vote-000013F3-QINU`"', '"`UNIQ--vote-000013F4-QINU`"'
'"`UNIQ--vote-00001414-QINU`"', '"`UNIQ--vote-00001415-QINU`"', '"`UNIQ--vote-00001416-QINU`"', '"`UNIQ--vote-00001417-QINU`"', '"`UNIQ--vote-00001418-QINU`"'
'"`UNIQ--vote-0000143C-QINU`"', '"`UNIQ--vote-0000143D-QINU`"', '"`UNIQ--vote-0000143E-QINU`"', '"`UNIQ--vote-0000143F-QINU`"', '"`UNIQ--vote-00001440-QINU`"', '"`UNIQ--vote-00001441-QINU`"'
'"`UNIQ--vote-0000145E-QINU`"', '"`UNIQ--vote-0000145F-QINU`"', '"`UNIQ--vote-00001460-QINU`"'
'"`UNIQ--vote-0000147C-QINU`"', '"`UNIQ--vote-0000147D-QINU`"', '"`UNIQ--vote-0000147E-QINU`"'
'"`UNIQ--vote-0000149A-QINU`"', '"`UNIQ--vote-0000149B-QINU`"', '"`UNIQ--vote-0000149C-QINU`"'
'"`UNIQ--vote-000014BE-QINU`"', '"`UNIQ--vote-000014BF-QINU`"', '"`UNIQ--vote-000014C0-QINU`"', '"`UNIQ--vote-000014C1-QINU`"', '"`UNIQ--vote-000014C2-QINU`"'
'"`UNIQ--vote-000014DF-QINU`"', '"`UNIQ--vote-000014E0-QINU`"', '"`UNIQ--vote-000014E1-QINU`"'
'"`UNIQ--vote-000014F9-QINU`"'
'"`UNIQ--vote-00001515-QINU`"', '"`UNIQ--vote-00001516-QINU`"'
'"`UNIQ--vote-0000152F-QINU`"'
'"`UNIQ--vote-0000154B-QINU`"', '"`UNIQ--vote-0000154C-QINU`"'
'"`UNIQ--vote-00001567-QINU`"'
'"`UNIQ--vote-00001582-QINU`"'
'"`UNIQ--vote-0000159D-QINU`"', '"`UNIQ--vote-0000159E-QINU`"'
'"`UNIQ--vote-000015B6-QINU`"'
'"`UNIQ--vote-000015D0-QINU`"'
Search
starting dose:
10 mg ~1 h before sexual activity (1)
preparations:
2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1)
fda max:
(Click arrow to add another value)
None
·
Indication-specific
·
40 mg/d
·
10 mg/d
· 20 mg/d ·
80 mg/d
·
10 mg/d (adults)
·
100 mg/d
·
4 g/d
·
400 mg/d
·
40 mg/d typical; up to 240 mg/d for Zollinger-Ellison
·
5 mg/d
·
50 mg/d
·
600 mg/d
·
No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals
·
No fixed maximum; titrated to TSH target
·
TID per eye
·
Titrated to glucose; no fixed ceiling
·
Titrated to glucose; no fixed maximum
·
'''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60
Other values:
'''4.5 mg/kg (without epinephrine), 7 mg/kg (with epinephrine)''' for infiltration; serum level monitoring required for prolonged IV antiarrhythmic use
0.5 mg/d
0.8 mg/d (rarely needed)
1 capsule BID (40 mg DXM / 20 mg quinidine per day)
1 drop per eye q8-12h
1 drop/eye/day (more frequent dosing reduces efficacy)
1 g/d (oral); 6 g/d (IV)
1 mg/d
1 mg/d typical Rx; higher in specific indications
1.8 mg in any 1-hour period (acute gout); 1.2 mg/d (prophylaxis with renal/hepatic impairment); much lower with strong CYP3A4 or P-gp inhibitors
1.8 mg/day SC (Victoza, T2DM)'"`UNIQ--ref-00000185-QINU`"' · 3.0 mg/day SC (Saxenda, obesity)'"`UNIQ--ref-00000186-QINU`"'
10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID
10 mg per 24 h
10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors)
10 mg/day (IR); 12.5 mg/day (CR)
10 mg/day (anxiety, oral)
10 mg/kg q2w
10 µg twice daily (Byetta)'"`UNIQ--ref-000000E7-QINU`"' · 2 mg once weekly (Bydureon BCise)'"`UNIQ--ref-000000E8-QINU`"'
100 mcg/d typical
100 mg/d (ED); 20 mg TID (PAH)
100 mg/d (rarely used)
100 mg/day (adult)
100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower)
100 mg/day (vertigo)
100-200 mg/day depending on indication
1000 mg/d (osteoarthritis); 1200 mg/d (rheumatoid arthritis)
12 inhalations/d (rescue); higher for severe exacerbation under monitoring
12 puffs MDI/d typical; nebulized 2000 mcg/d
120 mg/d (ER); IR not for chronic hypertension
120 mg/day (IV/IM); 40 mg/day (oral); '''5-day maximum total combined therapy''' to mitigate the GI bleeding, AKI, and platelet dysfunction risks
1200 mg/day (adult seizures); 1600 mg/day (bipolar mania)
140 mg/month
1400 mg q4w
15 mg/day (oral); 30 mg IV once daily (Anjeso)
15 mg/wk SC'"`UNIQ--ref-000002FE-QINU`"''"`UNIQ--ref-000002FF-QINU`"'
150 mg/d
150 mg/d (treatment)
150 mg/day (oral); use lowest effective dose for shortest duration per FDA NSAID class guidance
150 mg/day; therapeutic plasma-level monitoring recommended (target 50-150 ng/mL window)
1500 mg/day (Rx); 660 mg/24h (OTC, without provider direction)
16 mg/d (8 mg/d OTC)
16 mg/d (IR); 8 mg/d (XL)
16 mg/day (schizophrenia, adult); 6 mg/day (bipolar maintenance, autism irritability)
160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications
160 mg/d (rarely tolerated due to anticholinergic effects)
1600 mg/day (theoretical seizure dosing); practical use 400 mg/day for seizures, 100-200 mg/day for migraine prophylaxis
18 mg olanzapine / 75 mg fluoxetine per day
180 mg/d (adults)
195 units/treatment for chronic migraine; max varies by problem
2 g/d (Niaspan); higher off-label use historical
2 g/d typical
2 g/day (seizures); typically much lower for essential tremor
2 mg/wk SC (Ozempic)'"`UNIQ--ref-0000024B-QINU`"' · 2.4 mg/wk SC (Wegovy)'"`UNIQ--ref-0000024C-QINU`"' · 14 mg PO daily (Rybelsus)'"`UNIQ--ref-0000024D-QINU`"'
2 sprays/nostril BID
2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache
2 tablets/day (dextromethorphan 90 mg / bupropion 210 mg)
2.4 g/d
2.4 mg/day (HTN, IR); 0.4 mg/day (ADHD, Kapvay)
20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH)
20 mg/d (hypertension); 10 mg/d (other indications typical)
20 mg/day (IR); 28 mg/day (XR)
20 mg/day (adult); 10 mg/day in elderly and in hepatic impairment
20 mg/day (oral)
20 mg/day (seizures); commonly limited to 4 mg/day for anxiety in current practice
200 mg/d
200 mg/d (100 mg/d if on CYP3A4 inhibitors)
200 mg/d typical practical ceiling
200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra)
200 mg/day (typical adult oral)
2000 mg/d
225 mg/day outpatient (XR); 375 mg/day inpatient (IR divided TID); 75 mg/day in moderate hepatic impairment
23 mg/day
24 mg/day (Parkinson disease); 4 mg/day (restless legs syndrome)
24/6 mg/d (most labels)
240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster
240 mg/d (mononitrate ER); 160 mg/d (dinitrate)
240 mg/day
2400 mg/day (adult)
2400 mg/day (oral); 300 mg total per IV bolus dosing series
25 mg/d
25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label)
250 mg/d
2550 mg/d (IR); 2000 mg/d (ER)
28/10 mg/d
290 mcg/d
3 g/d (zoster)
3 g/d typical; higher in severe infections under specialist guidance
30 mg/24 hours
30 mg/d (XL) typical
30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d
30 mg/d for short-term use
30 mg/day (IR or ER)
30 mg/day (adult schizophrenia); 15 mg/day (MDD adjunct)
300 mg/d
300 mg/d typical practical limit (toxicity rises sharply above)
300 mg/day (IR or CR)
300 mg/day (depression, hospitalized); 150 mg/day outpatient; 6 mg/day for insomnia
300 mg/day (historical hospitalized inpatient depression); 150 mg/day outpatient typical ceiling
300 mg/day (oral)
300 mg/quarter
3000 mg/day
32 mg naltrexone / 360 mg bupropion per day
32 mg/day adult; weight-based pediatric ceiling
320 mg/d (hypertension); 320 mg/d (HF)
3200 mg/day (Rx); 1200 mg/day (OTC, without provider direction)
34 mg/d
35.6 mg/d
36 mg/day in three divided doses; single dose maximum 16 mg
360 mg/day
3600 mg/day; off-label doses higher are common but bioavailability saturates well below this
37.5 mg/d
4 L per procedure (standard-volume products)
4 g/d (rarely tolerated due to GI effects)
4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use
4 g/d typical
4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct)
4% topical; limit duration of use
4.5 mg/day (Parkinson disease); 0.5 mg/day (restless legs syndrome)
4.5 mg/wk SC'"`UNIQ--ref-00000055-QINU`"'
4.8 g/d (IV severe infection)
40 mg every week (selected indications); otherwise 40 mg every other week
40 mg/d (IR; doses >15 mg given as divided BID); 20 mg/d (XL)
40 mg/d (rarely needed; 40 mg restricted to patients not at goal on 20 mg)
40 mg/d standard; 80 mg/d restricted to patients tolerating 80 mg for ≥12 months without myopathy (post-SEARCH 2011 FDA restriction)
40 mg/d typical; up to 360 mg/d for Zollinger-Ellison
40 mg/day (oral, anxiety)
400 mg/d (acute primary aldosteronism diagnosis); 100-200 mg/d typical chronic
400 mg/d (pediatric); 600 mg/d (adult)
400 mg/d (rarely used)
400 mg/d typical maintenance; weight-adjusted ceiling per ophthalmology guidance
400 mg/day (IR, adult); 300 mg/day (ER); 300 mg/day in elderly >75 years
400 mg/day (bipolar monotherapy); 700 mg/day (epilepsy with enzyme-inducing comedication)
400 mg/day for chronic indications; higher for short-term acute pain
400 mg/day outpatient; 600 mg/day inpatient
400 mg/day theoretical; in practice rarely exceeds 200 mg/day
4000 mg/day (analgesic)
42 mg/d
420 mg/month
45 mg/d
45 mg/day
450 mg/day; doses above this raise seizure risk steeply
5 mg/d (adults)
50 g/week (cream/ointment); 2-week continuous limit; 4-week maximum cumulative
50 mg BID in heart failure (or once-daily equivalent CR); 25 mg BID in hypertension
50 mg/d (hypertension); up to 200 mg/d (edema)
50 mg/d × 14 d
50 mg/day (IR); 62.5 mg/day (CR); 60 mg/day (OCD)
50 mg/day (no efficacy benefit shown for higher doses despite the 100 mg strength being available)
500 mg/d (typical regimen); single 2 g for Zmax; 2 g for select STIs
6 capsules/d (300 mg butalbital, 1950 mg acetaminophen, 240 mg caffeine)
6 capsules/d (300 mg butalbital, 1950 mg aspirin, 240 mg caffeine)
6 mg/d (psychosis/mania); 3 mg/d (depression adjunct)
60 mg/d typical
60 mg/day
60 mg/day (oral, hypertension); 0.5% BID (ophthalmic)
60 mg/kg/d (typically up to 3000 mg/d)
600 mg/d typical practical ceiling in heart failure
600 mg/day (seizures); 450 mg/day (fibromyalgia and neuropathic pain)
640 mg/d (HTN); 240 mg/d (migraine)
675 mg/quarter
7 mg/day in children and adolescents; weight-based ceiling (~0.12 mg/kg/day) applies in smaller patients
70 mg/day
70 mg/week treatment; 40 mg/d for 6 months in Paget's
75 mg per dose; one dose per 24 hours (acute); one dose every other day (preventive)
75 mg/d maintenance (loading doses are single events)
750 mg/d
8 g/day (oral, short-term load); 6 g/day (chronic)
8 mg/d
8 tablets/d (300 mg tramadol / 2600 mg acetaminophen); 5-day duration limit per label
80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions)
80 mg/day oral (higher off-label)
800 mg/d
800 mg/d (rarely needed)
800 mg/d (severe invasive disease)
800 mg/day
84 mg per session
9 g/night
90 mg BID (acute year); 60 mg BID (chronic post-MI)
Acetaminophen 4 g/d absolute (3 g/d conservative); oxycodone titrated to effect
Acetaminophen 4 g/d absolute; codeine 240-360 mg/d typical practical limit
Aspirin GI/bleeding-limited; oxycodone titrated to effect
BID topical; once daily nail lacquer
Formulation-dependent
Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen)
Formulation-specific; ~4.8 g/d typical maximum oral
ICS 880 mcg/d (asthma); intranasal 200 mcg/d
ICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard
IV peripheral 10 mEq/h (40 mEq/L); IV central 20 mEq/h with cardiac monitoring; PO single doses generally ≤40 mEq
IV: monitored by levels (trough <1 mg/L for extended-interval; <2 mg/L for traditional)
Indication-dependent; 200-400 mg/d oral typical
Indication-specific; ACLS no fixed cumulative ceiling
Indication-specific; HE may require high-volume dosing
Indication-specific; bowel prep regimens reach 4 L cumulative
Indication-specific; high-dose IV regimens for encephalitis or disseminated disease
Indication-specific; lowest effective dose for shortest duration is the WHI-era standard
Indication-specific; renal clearance limits tolerable cumulative dosing
Indication-specific; titrated to effect
Intranasal 200 mcg/d (adults); inhaled 880 mcg/d
Limit to 48 hours of use to avoid hemolysis and methemoglobinemia
Limit topical to 10-day courses to reduce resistance pressure
N/A (never approved)
N/A (no current medical indication)
No fixed maximum; cumulative-dose toxicity drives all chronic decisions
No fixed maximum; titrated to INR target
No fixed maximum; titrated to clinical endpoints
No fixed maximum; titrated to pH and bicarbonate level; chronic high oral doses cause metabolic alkalosis and volume overload
No fixed maximum; titrated; sodium correction rate in chronic hyponatremia must not exceed 8-10 mEq/L per 24 hours to avoid osmotic demyelination
No strict ceiling for water-soluble vitamin; UL not set
No strict ceiling; water-soluble vitamin, low toxicity
No strict; Institute of Medicine UL 4,000 IU/d in adults for chronic use
Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing
Not formally established (dietary supplement); doses above ~3-5 mg show no additional efficacy but increase next-day sedation risk
Not strictly fixed; long-term Upper Limit ~4,000 IU/d in adults (Institute of Medicine)
Not yet approved
Once daily (Pataday 0.7%); BID (other ophthalmic)
One dose per day
One drop per eye per day
Oral maintenance 400 mg/d typical; higher in refractory cases
Per formulation
Rheumatologic ~25 mg/week; oncology indication-specific
Single 200-400 mcg/kg per dose for systemic indications
Single 60-hour course
Single doses ≤16 mg (FDA 2012 advisory withdrew the 32 mg single IV dose for QT-prolongation risk); 24-32 mg/d divided
Titrated to glucose
Titrated; risk of hypercalcemia is the limiting factor
Topical: BID; troche: 5×/day
Topical: nightly; oral APL: 45 mg/m²/d
Topical: nightly; systemic: regimen-specific
Topical: per formulation; oral supplement age-dependent
Topical: regimen-specific; oral: 400 mg/d in remaining specialty indications
Transplant: regimen-specific
UL 1000 mg (~1500 IU natural)/d in adults; routinely exceeded in older AREDS-1 trials
UL 2000 mg/d in adults
Withdrawn 2024
XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"'
~10 mg/d typical
~1500 mg/d (oral); 1200 mg/d (IV)
~200 mg elemental iron/d typical practical limit
~200 mg/d for most indications; higher doses for severe infections
~2500 mg elemental/d combined diet + supplements (chronic; UL)
~4 g/d (severe systemic infection)
~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster
~480 mg/d (oral); IV per protocol
~500 mg/d typical
Search
routes:
Oral (1)
onset:
~30 min (1)
duration:
4–5 h (1)
halflife:
4–5 h (1)
bioavailability:
~15% (extensive hepatic first-pass) (1)
pregnancy:
Category B (1)
legal:
Rx-only in US (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.
Search
Search
Drilldown: Medicines
Add topic
generic:
uses: (Click arrow to add another value)